These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 14697944)
1. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone. Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944 [TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M Transplant Proc; 2003 Sep; 35(6):2219-21. PubMed ID: 14529894 [TBL] [Abstract][Full Text] [Related]
4. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Hryszko T; Malyszko J; Malyszko JS; Brzosko S; Pawlak K; Mysliwiec M Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176 [TBL] [Abstract][Full Text] [Related]
5. Some aspects of hemostasis in CAPD patients treated with erythropoietin. Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426 [TBL] [Abstract][Full Text] [Related]
6. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M Transplantation; 1996 Sep; 62(6):828-30. PubMed ID: 8824484 [TBL] [Abstract][Full Text] [Related]
7. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569 [TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. Małyszko J; Tymcio J Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171 [TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223 [TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients. Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717 [TBL] [Abstract][Full Text] [Related]
11. Treatment with everolimus is associated with a procoagulant state. Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938 [TBL] [Abstract][Full Text] [Related]
12. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone. Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543 [No Abstract] [Full Text] [Related]
13. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients. Małyszko J; Łebkowska U; Małyszko JS; Myśliwiec M Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236 [TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolytic and inhibitory profiles in renal transplant recipients: comparison of cyclosporine and azathioprine. Vaziri ND; Ismail M; Martin DC; Gonzales E Int J Artif Organs; 1992 Jun; 15(6):365-9. PubMed ID: 1639529 [TBL] [Abstract][Full Text] [Related]
15. Possible relations between thyroid function, endothelium, and kidney and liver function in kidney allograft recipients. Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M Transplant Proc; 2006 Dec; 38(10):3509-13. PubMed ID: 17175317 [TBL] [Abstract][Full Text] [Related]
16. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. Sartori TM; Maurizio PG; Sara P; Ugolino L; Annalisa A; Panagiotis T; Massimo F; Antonio G J Heart Lung Transplant; 1999 Jul; 18(7):693-700. PubMed ID: 10452346 [TBL] [Abstract][Full Text] [Related]
17. Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression. Gómez E; de Oña M; Mélon S; Alvarez R; Laures A; Rodríguez M; Pobes A; Alvarez-Grande J Nephron; 1999; 82(3):238-45. PubMed ID: 10395996 [TBL] [Abstract][Full Text] [Related]
18. The effect of cyclosporine on regulators of fibrinolysis in plasma from renal allograft recipients. Elhasade AS; Perkowska A; Paczek L; Rowiński W; Soluch L; Szmidt J; Gałazka Z; Gaciong Z Ann Transplant; 1998; 3(1):13-8. PubMed ID: 9869892 [TBL] [Abstract][Full Text] [Related]
19. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients. Sartori MT; Patrassi GM; Rigotti P; Marchini F; Fioretti M; Spiezia L; Girolami A Transplantation; 2000 May; 69(10):2116-21. PubMed ID: 10852608 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]